ReproNovo has raised $65 million in Series A financing led by Jeito Capital to advance two Phase 2-ready compounds targeting male infertility, adenomyosis, and embryo implantation success.
Mereo BioPharma's partner, Ultragenyx, anticipates completing enrollment for the Phase 3 Orbit study of setrusumab in Osteogenesis Imperfecta (OI) by the end of Q1 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.